Background: Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A 1c (HbA1c) was measured on day 1 (baseline) and at weeks 6 and 12.
INTRODUCTION I
MPROVEMENT IN METABOLIC CONTROL, as measured by reductions in hemoglobin A 1c (HbA1c), has been shown to decrease the incidence and progression of both micro-and macrovascular complications of diabetes. [1] [2] [3] [4] [5] In the Diabetes Control and Complications Trial (DCCT), intensive insulin therapy significantly reduced retinopathy (47-76%), microalbumin-uria (39%), albuminuria (54%), and neuropathy (60%). Further analysis of DCCT data suggests that HbA1c may not be responsible for all of the improvements seen in the intensively treated group, and the authors went on to suggest that glucose excursions may play a role in the development of complications due to diabetes. 5 It has also been suggested that glycemic control may be more appropriately expressed in terms of glucose variability in conjunction with HbA1c, rather than by HbA1c alone. [6] [7] [8] Hypoglycemia is the main limiting factor in the glycemic management of insulin-treated diabetes subjects. 9 In the DCCT, for instance, attempts to achieve near-normal glucose levels resulted in a 3.3-fold increase in the rate of severe hypoglycemia. Frequent self-monitoring of blood glucose (SMBG) is an integral part of intensive diabetes management that has been shown to improve glycemic control. 10 Patients, however, dislike frequent SMBG because of the associated pain, inconvenience, and intrusive nature of SMBG. Recent availability of continuous glucose monitoring (CGM) devices has given patients the ability to view real-time glucose values, to review trend graphs of recent glucose values, and to receive alarms/alerts of impending hypo-or hyperglycemia. Preliminary clinical evidence suggests that use of continuous glucose data results in reductions in HbA1c. [11] [12] [13] [14] [15] [16] [17] [18] [19] Most of these studies, however, have relied upon retrospective review of CGM data to modify therapy 12, 15, 16, 20 or enrolled only pediatric subjects. 13, 14, 17, 18, 21, 22 Two previously published studies involving a 3-day 23 and 7-day 24 CGM device (STS ® System, DexCom, Inc., San Diego, CA) that provides continuous glucose values, trends, and alerts to users in real-time showed significant improvements in the proportion of time spent in target range glycemia coupled with significant reductions in the proportion of time spent both hyper-and hypoglycemic. Herein, we report the results of a study involving the use of the 3-day version of this real-time CGM device by adult subjects with type 1 and type 2 diabetes mellitus. Metabolic control, as measured by HbA1c, was assessed at baseline, at 6 weeks, and at the conclusion of this 12-week study.
SUBJECTS AND METHODS

Study population
One hundred forty subjects were enrolled in this multicenter U.S. study. Individuals younger than 18 years old and those who were pregnant or lactating or with a contraindication to using the CGM (known allergy to medical adhesives or dermatological conditions that would preclude wearing sensors on unaffected skin) were excluded. The protocol was approved by the Institutional Review Boards of all centers, and all subjects provided witnessed, written informed consent prior to enrollment. Subjects were 45.4 Ϯ 13.67 (mean Ϯ SD) years old, and 64 (45.7%) were men. Subjects had a diagnosis of diabetes for 20.2 Ϯ 11.38 years; 109 (77.9%) had type 1 diabetes, and 31 (22.1%) had type 2 diabetes. Fifty-eight (41.4%) delivered insulin via multiple daily injections (MDI), 75 (53.6%) were on continuous subcutaneous insulin infusion (CSII) pumps, and seven (5.0%) were treated with oral agents only. Height was 169.7 Ϯ 9.4 cm, weight was 82.0 Ϯ 21.6 kg, and body mass index was 28.4 Ϯ 6.8 kg/m 2 . At baseline, subjects reported performing SMBG 5.0 Ϯ 2.6 times per day and had a mean HbA1c of 7.6 Ϯ 1.2%.
Procedures
Real-time CGM with the STS System was studied in adults with diabetes over a 12-week period of home use. HbA1c was measured on day 1 (baseline) and at weeks 6 and 12. Measurement of HbA1c was performed per routine at each enrolling center; no core laboratory was used. On study day 1, participants received the CGM device and underwent training on proper use. Insertion of the first sensor was performed under staff supervision. Subjects inserted subsequent sensors on their own at home. Study participants were given supplies sufficient for 3 weeks of device use. Throughout the study, subjects were instructed to use CGM data as an adjunct to, and not as a replacement for, SMBG fingersticks when making diabetes-related treatment decisions (e.g., insulin dose modifications). Follow-up visits were performed at 3-week intervals for resupply of device-related materials, to document interval adverse events, and to download CGM data. The final study visit occurred at the end of week 12.
Sensor and transmitter
The STS Sensor consists of an applicator, sensor probe, and transmitter housing as previously described. 23, 24 The applicator is a singleuse disposable unit that houses the introducer needle and the sensor probe contained within it. The transmitter housing was adhered to the patient's abdomen, and the needle (containing the sensor probe) was then inserted into the subcutaneous tissue of the abdomen. The needle was retracted, and the applicator was removed, leaving the sensor probe within the subcutaneous tissue. After the transmitter was installed, an averaged glucose signal was wirelessly sent to the receiver via low-powered radiofrequency at 5-min intervals.
Receiver
The STS Receiver is an externally worn pager-sized device. For the purposes of this study, the receiver used uploaded SMBG meter values for calibration (i.e., to convert the glucose signal measured by the sensor into a user-viewable glucose concentration). Two hours after the sensor was first inserted, two SMBG values were uploaded for calibration. Thereafter, patients were instructed to upload at least one SMBG value every 12 h. Once calibrated, the receiver displayed a glucose value that was updated at 5-min intervals. The receiver also displayed glucose trend graphs of the preceding 1, 3, or 9 h and generated high and low glucose alerts and alarms. In this study, subjects were allowed to modify the high glucose alert (range 140-400 mg/dL in increments of 20 mg/dL, or no high alert) as well as the low glucose alert (60-90 mg/dL in increments of 10 mg/dL, or no low alert). A nonmodifiable hypoglycemia alarm was triggered at glucose levels Յ55 mg/dL.
Statistical analysis
Analyses of HbA1c change from baseline were performed using SAS ® Software, version 9.1.3 (SAS Institute, Inc., Cary, NC). All statistical comparisons were conducted at the ␣ ϭ 0.05 level of significance using two-tailed tests, unless otherwise stated. The P values for HbA1c reductions were calculated using a linear mixed model using the change in HbA1c from baseline as the dependent variable, baseline HbA1c as a covariate, week of measurement as an independent variable, subject as a random effect, and an unstructured covariance model. For exploratory analyses of CGM use relative to HbA1c reduction, the bottom quartile and top quartile of each distribution assessed (1-, 3-, and 9-h trend screen views, and all trend screen views combined) were compared using a two-sample t test of means, using a two-tailed alternative hypothesis at an ␣ level of 0.05.
RESULTS
HbA1c change from baseline
The mean Ϯ SD number of sensors used per subject over the 12-week study was 23.8 Ϯ 7.8 (approximately two sensors per week). Results of observed HbA1c reductions are presented in Table 1 . Over 12 weeks, the overall cohort reduced HbA1c by 0.4 Ϯ 0.05% (P Ͻ 0.0001). A reduction in HbA1c relative to baseline was observed in all evaluated subgroups and was statistically significant in all but two subgroups. Table 1 also shows that most of the reduction in HbA1c took place during the first 6 weeks after enrollment, and was sustained through the end of week 12. Both subgroups with baseline HbA1c above target American Diabetes Association values of 7.0% reduced their 12-week HbA1c. Subjects with baseline levels 7.0-9.0% lowered their HbA1c by 0.5 Ϯ 0.06% ( Fig. 1 shows an individual case sample), and those with baseline HbA1c Ͼ9.0% experienced a reduction of 1.4 Ϯ 0.4%.
An exploratory analysis of the relationship between the amount of CGM attention and the magnitude of HbA1c reduction was performed. For all subjects, CGM attention was quantified by calculating the average number of glucose trend screen views (1-h, 3-h, 9-h, and all three combined) performed per day. Sub-jects in the top quartile of CGM attention by this measure were compared to those who fell in the bottom quartile. Table 2 shows that, in all cases, the top quartile of CMG users (in terms of frequency of trend screen views) experienced a greater reduction in 12-week HbA1c than those in the bottom quartile (P Ͻ 0.05 for each comparison).
Safety evaluation
Over the 12-week duration of this study, 41 adverse events were reported for 35 subjects (25.0%). Five hypoglycemic events requiring third-party assistance were experienced by four subjects; three were considered "not related" to the CGM device, and two were deemed "probably not related" by site investigators. In four of the five instances of hypoglycemia requiring assistance, CGM provided the user with low glucose alerts and alarms; the CGM system was not in calibration during the remaining episode. Overall, four adverse events were considered "probably related" to the CGM device: two were episodes of bleeding, one was erythema at a sensor insertion site, and one was edema at the sensor insertion site. All five of these device-related events were rated as "mild" in severity and resolved without treatment.
In terms of safety, it is also noteworthy that subjects did not increase the amount of time spent hypoglycemic (Ͻ70 mg/dL) during study participation. The amount of time spent BAILEY ET AL. 206 
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CONCLUSIONS
This observational study showed an improvement in metabolic control in adults using real-time CGM at 6 weeks that was sustained at 12 weeks. Earlier reports were either on retrospective CGM systems or involved pediatric subjects using real-time CGM. [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] From the most recently published data of real-time CGM use in children, 25 the DirecNet Study Group concluded that, while the point accuracy of CGM does not yet equal that of SMBG meters, the technology has the potential to be an important adjunct to the management of youth with type 1 diabetes.
In terms of metabolic control, Deiss et al. 19 recently reported an improvement in HbA1c in both adults and children who used realtime CGM over a 3-month period. In that study, however, all subjects had type 1 diabetes and had a baseline HbA1c Ն8.1%. The present study enrolled subjects with both type 1 and type 2 diabetes who had a broader range of metabolic control at baseline. Results (Table 1) indicate that individuals with type 2 diabetes experienced a significant HbA1c reduction, and subjects with baseline HbA1c in the range of 7.0-9.0% also benefited. The hypoglycemia exposure analysis showed that the overall cohort did not increase time spent Ͻ70 mg/dL across the 12 weeks of this study. Hence, the observed reductions in HbA1c were obtained without an increased risk of hypoglycemia. This observation is supported by previous studies 23, 24 that showed improved glycemic control can be accomplished with real-time CGM while significantly reducing hypoglycemic exposure. Most of the observed HbA1c reduction took place within the first 6 weeks of this study, which again is in keeping with prior studies by Garg et al. 23 and Garg and Jovanovic, 24 which showed that improvements in glycemic control were realized within 6 days 23 or 14 days 24 of access to real-time CGM data. Subjects using both MDI and CSII experienced statistically significant reductions in HbA1c. This indicates that use of an insulin pump is not required to derive benefit from real-time CGM. Subjects with baseline HbA1c Ͼ9% experienced the greatest reduction in HbA1c (1.4 Ϯ 0.4%), thereby demonstrating that individuals with poor metabolic control can benefit from real-time CGM. These results indicate that use of real-time CGM need not be restricted to intensively managed patients on CSII therapy. This study's finding that subjects with higher baseline HbA1c experienced a greater reduction in HbA1c is consistent with the pattern previously described by Tsui et al. 26 The primary limitation of this study is the fact that it did not enroll a control group; therefore a causal link between CGM use and HbA1c reduction cannot be proven. Nevertheless, the results presented in Table 2 suggest a "dose-response" relationship between the two that provides evidence in favor of causality. These data show that subjects who used CGM more intensively, in terms of frequency of trend screen views, experienced significantly greater reductions in HbA1c relative to subjects falling in the bottom quartile of CGM use.
We feel that the results of this study show that real-time CGM has the potential to help a wide range of individuals with diabetes safely lower their HbA1c. This observational study forms a compelling basis for formal hypothesis testing in large-scale randomized, controlled clinical trials of real-time CGM.
